These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 15790456)

  • 1. FDG-PET for management of cervical and ovarian cancer.
    Havrilesky LJ; Kulasingam SL; Matchar DB; Myers ER
    Gynecol Oncol; 2005 Apr; 97(1):183-91. PubMed ID: 15790456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
    Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
    Thrall MM; DeLoia JA; Gallion H; Avril N
    Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
    Kim CK; Park BK; Choi JY; Kim BG; Han H
    J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels.
    Bhosale P; Peungjesada S; Wei W; Levenback CF; Schmeler K; Rohren E; Macapinlac HA; Iyer RB
    Int J Gynecol Cancer; 2010 Aug; 20(6):936-44. PubMed ID: 20683399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
    Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated PET/CT for the evaluation of para-aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings.
    Yildirim Y; Sehirali S; Avci ME; Yilmaz C; Ertopcu K; Tinar S; Duman Y; Sayhan S
    Gynecol Oncol; 2008 Jan; 108(1):154-9. PubMed ID: 17945337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
    Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
    Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical impact of FDG-PET imaging in post-therapy surveillance of uterine cervical cancer: from diagnosis to prognosis.
    Chung HH; Kim SK; Kim TH; Lee S; Kang KW; Kim JY; Park SY
    Gynecol Oncol; 2006 Oct; 103(1):165-70. PubMed ID: 16574205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
    Sakurai H; Suzuki Y; Nonaka T; Ishikawa H; Shioya M; Kiyohara H; Katoh H; Nakayama Y; Hasegawa M; Nakano T
    Gynecol Oncol; 2006 Mar; 100(3):601-7. PubMed ID: 16257440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early detection of recurrent ovarian cancer in patients with low-level increases in serum CA-125 levels by 2-[F-18]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Liou WS; Liu RS; Hu C; Tsay DG; Liu CB
    Cancer Biother Radiopharm; 2011 Apr; 26(2):175-81. PubMed ID: 21510748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of 18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretherapeutic detection of occult para-aortic node involvement in patients with a locally advanced cervical carcinoma.
    Leblanc E; Gauthier H; Querleu D; Ferron G; Zerdoud S; Morice P; Uzan C; Lumbroso S; Lecuru F; Bats AS; Ghazzar N; Bannier M; Houvenaeghel G; Brenot-Rossi I; Narducci F
    Ann Surg Oncol; 2011 Aug; 18(8):2302-9. PubMed ID: 21347790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of 18F-FDG PET/CT imaging combined with detection of CA125 and HE4 in the diagnosis of recurrence and metastasis of ovarian cancer.
    Sun J; Cui XW; Li YS; Wang SY; Yin Q; Wang XN; Gu L
    Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7276-7283. PubMed ID: 32706065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-analysis: comparison of F-18 fluorodeoxyglucose-positron emission tomography and bone scintigraphy in the detection of bone metastasis in patients with lung cancer.
    Chang MC; Chen JH; Liang JA; Lin CC; Yang KT; Cheng KY; Yeh JJ; Kao CH
    Acad Radiol; 2012 Mar; 19(3):349-57. PubMed ID: 22173321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2-[Fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer.
    Zimny M; Siggelkow W; Schröder W; Nowak B; Biemann S; Rath W; Buell U
    Gynecol Oncol; 2001 Nov; 83(2):310-5. PubMed ID: 11606090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of recurrent uterine cervical cancer: PET versus PET/CT: a systematic review and meta-analysis.
    Ding XP; Feng L; Ma L
    Arch Gynecol Obstet; 2014 Oct; 290(4):741-7. PubMed ID: 24798933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients.
    Nanni C; Rubello D; Farsad M; De Iaco P; Sansovini M; Erba P; Rampin L; Mariani G; Fanti S
    Eur J Surg Oncol; 2005 Sep; 31(7):792-7. PubMed ID: 15893908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
    Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
    Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18 deoxyglucose positron emission tomography, magnetic resonance imaging and bone scintigraphy for the diagnosis of bone metastases in patients with lung cancer: which one is the best?--a meta-analysis.
    Liu T; Xu JY; Xu W; Bai YR; Yan WL; Yang HL
    Clin Oncol (R Coll Radiol); 2011 Jun; 23(5):350-8. PubMed ID: 21094027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of PET/CT is similar to that of conventional MRI and even better for detecting small peritoneal implants in patients with recurrent ovarian cancer.
    Sanli Y; Turkmen C; Bakir B; Iyibozkurt C; Ozel S; Has D; Yilmaz E; Topuz S; Yavuz E; Unal SN; Mudun A
    Nucl Med Commun; 2012 May; 33(5):509-15. PubMed ID: 22357440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.